Format

Send to

Choose Destination
Cell. 2010 Apr 2;141(1):13-7. doi: 10.1016/j.cell.2010.03.018.

It's diagnostics, stupid.

Author information

1
Division of Molecular Carcinogenesis, Center for Biomedical Genetics and Cancer Genomics Center, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. r.bernards@nki.nl

Abstract

To stem the spiraling cost of cancer treatment, a concerted effort is urgently needed to develop molecular diagnostics to better identify the patients that respond to expensive targeted therapies. Opportunities and obstacles in the development of such drug response biomarkers are discussed here.

PMID:
20371338
DOI:
10.1016/j.cell.2010.03.018
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center